Lonza and CELLution Biotech enter into long-term agreement
Swiss group Lonza and CELLution Biotech, of the Netherlands, have entered into a strategic partnership in the area of single use bioreactors with the signing of a global sales and distributor agreement that gives Lonza the global and exclusive marketing and sales rights for the CELL-tainer developed by CELLution Biotech.
Swiss group Lonza and CELLution Biotech, of the Netherlands, have entered into a strategic partnership in the area of single use bioreactors with the signing of a global sales and distributor agreement that gives Lonza the global and exclusive marketing and sales rights for the CELL-tainer developed by CELLution Biotech.
The CELL-tainer is a single use bioreactor with non-invasive sensors. It has an advanced mixing technology and novel, expandable processing volume within the same reactor run. These features will give the biopharmaceutical industry higher product yields in mammalian cell based processes.
Its superior gas exchange properties mean the CELL-tainer is also suited for microbial culture. In addi-tion, the linear scalability of this novel system will shorten the process development time of mammalian and microbial produced biopharmaceuticals signifi-cantly.
The 20-litre CELL-tainer will be mainly used in process development and pre-clinical production. The larger CELL-tainer, which will be launched later, could be used for the manufacturing of later stage clinical trial material and commercial productions.
"The CELL-tainer bioreactor system complements the Lonza Bioscience flexible packaging product range, offering our clients higher cell densities and higher productivity with cell cultures," said Roel Gor-dijn, global sales & marketing director for the business unit Media at Lonza Bioscience. "In addition the CELL-tainer bags are made from Lonza's proprietary Plati-num UltraPAK film material."